Q1 2026 Zydus Lifesciences Ltd Earnings Call Transcript
Key Points
- Zydus Lifesciences Ltd (BOM:532321) reported consolidated revenues of INR65.7 billion, marking a 6% year-on-year increase.
- The company's EBITDA margin remained strong at 31.8%, with an EBITDA of INR20.9 billion for the quarter.
- The US Formulations business showed sequential and year-on-year growth, with revenues of INR31.8 billion, up 3% year-on-year.
- The Branded Formulations business in India outpaced market growth with a 9% year-on-year increase, driven by strong performance in key therapeutic areas.
- International Markets Formulations business posted a robust 37% year-on-year growth, reflecting strong demand across emerging markets and Europe.
- The Consumer Wellness business faced challenges due to early monsoon conditions affecting seasonal brands, though the nonseasonal portfolio remained resilient.
- Despite a strong performance, the net profit growth was modest at 3% year-on-year, reaching INR14.7 billion.
- The company anticipates challenges in the US market due to price pressures on key products like Revlimid.
- There is uncertainty regarding the FY27 US revenue outlook, with potential impacts from the Revlimid cliff and ongoing litigation affecting product availability.
- The company faces potential risks from regulatory and market dynamics in emerging markets, which could impact future growth projections.
It's my pleasure to welcome you all to the (technical difficulty). For today's call, we have with us Dr. Sharvil Patel, Managing Director; Mr. Nitin Parekh, CFO; Mr. Tushar Shroff, President, Corporate Finance; Mr. Arvind Bothra, Head of Investor Relations; and Mr. Alok Garg from the Managing Director's office.
To begin with, let me now give you a broad overview of the developments during the quarter. We commenced FY26 on a strong note, following a formidable base of FY25. We delivered a stable revenue growth during the quarter, with most key businesses performing well. Our US Formulations business sustained execution excellence, delivering both sequential and year-on-year growth on a high base.
On the India geography front, our Branded Formulations business in India sustained the growth momentum, outpacing the market growth for yet another quarter. The business has consistently outperformed the market growth in the last couple of years.
Consumer Wellness business navigated through the challenges posed by early monsoon
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
